Abstract: The present disclosure relates to tissue supports for use with engineered tissues and organoids, such as cardiac organoid chambers. In an embodiment of the present disclosure, the tissue supports are provided with a fluid-impermeable resilient member that is resiliently deformable during testing by cultured tissues formed on the surface of the tissue support.

Abstract: Provided are multi-layer bioreactors for growing, maintaining, stimulating, monitoring and testing organoids and tissues derived from or representing hollow organs in organoid chambers. Also provided are uses of those bioreactors in modeling a disease process for monitoring disease progress and/or for assessing a biological effect, such as therapeutic efficacy and/or toxicity, e.g., organotoxicity. Also disclosed are bioreactors comprising organoid chambers that are useful as systems for measuring the volume, pressure, contractility, pump function, or electrophysiology of an organoid chamber as well as systems for controlling the pressure experienced by an organoid or tissue in an organoid chamber.

Abstract: Disclosed are methods of treating a subject having a biopsy-only glioblastoma tumor comprising applying an alternating electric field to a target site of the subject for a period of time, wherein the target site comprises one or more glioblastoma cells; administering a therapeutically effective amount of temozolomide (TMZ); and administering a therapeutically effective amount of a checkpoint inhibitor to the subject. Disclosed are methods of increasing survival of a subject having a biopsy-only glioblastoma tumor comprising applying an alternating electric field to a target site of the subject for a period of time, wherein the target site comprises one or more glioblastoma cells; administering a therapeutically effective amount of temozolomide (TMZ); and administering a therapeutically effective amount of a checkpoint inhibitor to the subject.

Abstract: Provided are multi-layer bioreactors for growing, maintaining, stimulating, monitoring and testing organoids and tissues derived from or representing hollow organs in organoid chambers. Also provided are uses of those bioreactors in modeling a disease process for monitoring disease progress and/or for assessing a biological effect, such as therapeutic efficacy and/or toxicity, e.g., organotoxicity. Also disclosed are bioreactors comprising organoid chambers that are useful as systems for measuring the volume, pressure, contractility, pump function, or electrophysiology of an organoid chamber as well as systems for controlling the pressure experienced by an organoid or tissue in an organoid chamber.

Abstract: A multi-sample system for engineered tissue strip assay includes a tissue module enabled with a set of channels each configured to house one or more tissue strips, each tissue strip is in contact with a sensor at one end and a tissue lengthening mechanism at the other end, the sensor is displaced or deformed when the tissue strip exerts force against the sensor during the lengthening or contraction of each tissue strip; and a detection system configured to capture change in the sensor in contact with the tissue strips during lengthening or contraction of at least one of the tissue strips.

Abstract: The present disclosure relates to tissue supports for use with engineered tissues and organoids, such as cardiac organoid chambers. In an embodiment of the present disclosure, the tissue supports are provided with a fluid-impermeable resilient member that is resiliently deformable during testing by cultured tissues formed on the surface of the tissue support.

Abstract: Provided are multi-layer bioreactors for growing, maintaining, stimulating, monitoring and testing organoids and tissues derived from or representing hollow organs in organoid chambers. Also provided are uses of those bioreactors in modeling a disease process for monitoring disease progress and/or for assessing a biological effect, such as therapeutic efficacy and/or toxicity, e.g., organotoxicity. Also disclosed are bioreactors comprising organoid chambers that are useful as systems for measuring the volume, pressure, contractility, pump function, or electrophysiology of an organoid chamber as well as systems for controlling the pressure experienced by an organoid or tissue in an organoid chamber.

Abstract: The disclosure provides a device for developing organized tissue strips, such as cardiac tissue strips, for high-throughput assays of functional performance and the methods involved in fabricating, assembling, implementing, utilizing and analyzing data from such assays. The disclosure further provides systems for constructing such devices, systems comprising those devices comprising cells and extracellular matrix material for developing organized tissue strips or comprising the devices and organized tissue strips. The disclosure further provides methods for assaying a property of a tissue strip, such as contractile force.

Abstract: A two-stage or two-tier system and method for rapid screening of compounds for inotropic effects is disclosed. The system comprises, in a first tier, an engineered cardiac tissue strip (CTS) comprising cardiomyocytes, such as human ventricular cardiomyocytes, embedded in a biocompatible gel wherein the gel comprises at least two biocompatible structural supports such as polydimethylsiloxane posts for elevating the gel. The system further comprises, in a second tier, an apparatus comprising at least one organoid module comprising at least one organoid cartridge, wherein each organoid cartridge comprises an organoid, and a minor arrangement. The system further comprises at least one detection device, such as a high-speed camera, for detecting deflection of the CTS gel in the first tier of the system and/or for detecting tissue or organoid behavior in the organoid cartridge or cartridges of the second tier of the system.